clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-90-91clinvest-535Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWИзменение позиции по применению гидроксихлорохина для профилактики и лечения COVID-19Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and preventionhttps://orcid.org/0000-0002-9307-4994МирзаевК. Б.MirzaevK. B.

Мирзаев Карин Бадавиевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8308-7599

Москва

Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202810202004SФармаCOVID9091Copyright © Мирзаев К.Б., Сычёв Д.А., 20202020Мирзаев К.Б., Сычёв Д.А.Mirzaev K.B., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/535

Следует ограничить применение гидроксихлорохина для профилактики и лечения COVID-19 в амбулаторном и стационарном звене в связи с недостаточными данными в пользу эффективности и неблагоприятным профилем безопасности препарата.

The use of hydroxychloroquine for COVID-19 treatment and prevention should be restricted in both out- and inpatient settings due to the lack of evidence for effectiveness and unfavorable safety profile.

коронавирусгидроксихлорохинCOVID-19coronavirushydroxychloroquineCOVID-19ReferencesGautret P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949Gautret P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949Yao X et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. DOI: 10.1093/cid/ciaa237Yao X et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. DOI: 10.1093/cid/ciaa237https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatmentshttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatmentshttps://www.fda.gov/drugs/drug-safety-and-availability/fda-cautionsagainst-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospitalsetting-orhttps://www.fda.gov/drugs/drug-safety-and-availability/fda-cautionsagainst-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospitalsetting-orhttps://www.tropmedres.ac/covid-19/copcov/copcov-key-messageshttps://www.tropmedres.ac/covid-19/copcov/copcov-key-messageshttps://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;NEJMoa2016638. DOI: 10.1056/NEJMoa2016638Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;NEJMoa2016638. DOI: 10.1056/NEJMoa2016638

The authors declare that there are no conflicts of interest present.